Évaluation des effets cardiovasculaires du liraglutide : Conception et données de base de l'étude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

LEADER® (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER® design is presented here.